Beyond Air Launches Pivotal Trial of LungFit Go Inhaled NO for NTM Lung Infections
Beyond Air has launched a pilot clinical trial evaluating its investigational therapy LungFit GO — inhaled nitric oxide that can be...
Defects in Mitochondria May Sustain Burkholderia Cenocepacia Infections in CF
Specific immune cells called macrophages in cystic fibrosis (CF) are unable to kill the bacteria Burkholderia cenocepacia due to...
CF Children With COVID-19 Usually Do Not Develop Serious Disease, Study Finds
Children with cystic fibrosis (CF) who become infected with SARS-CoV-2 — the virus that causes COVID-19 — usually have a mild disease...
BiomX Testing Potential Therapy for CF Lung Infections
BiomX has unveiled a platform designed for more rapid and efficient development of phage therapy, which the company is using to test...
Phase 3 ASPEN Trial Testing Brensocatib Now Recruiting; First Patient Dosed
The first participant has been dosed in ASPEN, a Phase 3 trial — now recruiting patients — that is evaluating the investigational...
Study Recommends Longer Rest Interval Between 6-min Walk Tests for Non-CF Bronchiectasis Patients
Two consecutive six-minute walk tests (6MWT) — which measure the distance a patient can walk in that time to assess their exercise...
Study Identifies Risk Factors of Malnutrition in Children With CF
Children with cystic fibrosis (CF) who are older, thinner, or have worse lung function may be at increased risk of malnutrition, a study...
Moscow Scientists Edge Closer To A Breakthrough For Cystic Fibrosis
Scientists at Moscow’s Bochkov Medical Genetic Research Center have successfully corrected a mutation of the CFTR gene, which causes...
Welcome to the team
MECFA welcomes Dr. Susanna A. McColley to our team to lead the MECFA Diagnostic Program. Susanna A. McColley, MD is Associate Chief...
Pegylation Provides Long‐acting Version of Dornase Alfa for CF Treatment
A modified version of Pulmozyme (dornase alfa), a widely-used cystic fibrosis (CF) therapy, lasts longer and reduces the need for...
